Navigation Links
Carilion Clinic Invests in Sight Saving Technology to Improve Patient Care: Carilion Clinic Teams Up with Retasure
Date:8/29/2008

Carilion Clinic teams up with Retasure

Wake Forest, NC (PRWEB) August 29, 2008 -- Digital Healthcare, a Wake Forest, NC company specializing in risk assessment for diabetics, recently announced that the Carilion Clinic of Virginia has selected the Retasure solution to provide retinal imaging risk assessment to diabetic patients.

Carilion Medical Group is one of the largest physician practices in Virginia, and is the largest primary care group in the state. It consists of more than 200 physicians, Nurse Practitioners and Physician Assistants in 70 offices across western Virginia and the Shenandoah Valley. The practice provides care to more than 2,500 diabetics in the region.

"Carilion Medical Group is a very important healthcare provider in this community," says Scott Sanner, Senior Vice President for Digital Healthcare's North American Operations. "They see a large number of patients at risk for vision loss, but it is estimated that up to half of these patients do not have regular eye exams. Being assessed for retinopathy through their PCP will undoubtedly lead to earlier detection -- and prevention -- of vision loss."

The FDA-approved and HEDIS compliant Retasure program provides a simple, affordable, and non-invasive solution that allows physicians to capture their patients' retinal images during a three to five minute procedure. Images are transmitted over a secure, HIPAA compliant network to an accredited reading center. A state-licensed and board-certified ophthalmologist reviews the images and results are returned to the original physician within 72 hours.

There are an estimated 20 million diabetic patients in the US, but only about half have any retinal assessments, despite a high risk of diabetic retinopathy. The National Eye Institute indicates diabetic retinopathy is the leading cause of blindness among working age American adults. More than a million patients around the world have received a retinal risk assessment using Digital Healthcare software.

About Digital Healthcare
Digital Healthcare is the global leader in retinal risk assessment. They are the world's leading provider of care management programs for diabetic retinopathy. Their award-winning MS-HUG technology is used by leading hospitals and research centers including University Hospitals Case Medical Center at Case Western Reserve University, The Wilmer Eye Institute at The Johns Hopkins University and the United States Military. Digital Healthcare's Retasure solution offers several advantages for primary care and endocrinologist physicians and their patients: It can be operated by non-clinicians; it is non-invasive and requires no dilation; it obtains exceptionally high-quality digital images of the retina using a simple-to-operate fundus camera; it returns results quickly to the ordering physicians; and it encourages patient compliance for retinal evaluation and comprehensive eye examinations.

For additional information, please visit www.retasure.com.

# # #

Read the full story at http://www.prweb.com/releases/2008/08/prweb1257154.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
11. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016  Renova™ Therapeutics, a biotechnology ... failure and type 2 diabetes, announced that it ... adeno-associated virus (AAV) vector developed in the laboratory ... at Stanford University. The company plans to use ... therapy product pipeline. "Early research ...
(Date:12/8/2016)... CARDIFF, UK (PRWEB) , ... December 08, 2016 ... ... high precision light to control cells — optogenetics — is key to exciting ... state of the art, spatially patterned light projected via free-space optics stimulates small, ...
(Date:12/8/2016)... OXFORD, England , December 8, 2016 /PRNewswire/ ... (OGT), das Unternehmen für Molekulargenetik, erweitert seine Palette ... SureSeq myPanel™ NGS Custom FH Panels, das ein ... Hypercholesterinämie (FH) ermöglicht. Das Panel bietet eine Erkennung ... Number Variations (CNV) mit einem einzigen kleinen Panel ...
(Date:12/8/2016)... , Dec. 8, 2016  Anaconda BioMed S.L., a ... of the next generation neuro-thrombectomy system for the treatment ... Tudor G. Jovin, MD to join its Scientific Advisory ... a strategic network of scientific and clinical experts to ... of the ANCD BRAIN ® to its clinical ...
Breaking Biology Technology:
(Date:11/22/2016)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that the company has ... Sciences Awards as "Most Outstanding in eClinical Solutions" ... of recognition and growth for MedNet, which has effectively ... iMedNet ™ , MedNet,s flagship eClinical ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is to ... for Private Biobanks shows the highest Compounded Annual Growth Rate ... region during the analysis period 2014-2020. North ... of 9.95% followed by Europe at ...
(Date:11/15/2016)... Md. , Nov. 15, 2016  Synthetic ... company developing therapeutics focused on the gut microbiome, ... offering of 25,000,000 shares of its common stock ... common stock at a price to the public ... proceeds to Synthetic Biologics from the offering, excluding ...
Breaking Biology News(10 mins):